Tumor cells in pleural effusion and peripheral blood of malignant pleural mesothelioma patients
Recruiting
- Conditions
- Malignant pleural mesotheliomaMesotheliomaPleural effusion tumor cellsCirculating tumor cellsCirculating endothelial cellsAsbestkankerMaligne pleuraal mesothelioom
- Registration Number
- NL-OMON20403
- Lead Sponsor
- Erasmus MC Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Age ≥ 18 years
- Patient requiring a pleural drainage or VATS as a part of standard care
Exclusion Criteria
None
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the use of a modified CellSearch enrichment for the enumeration of pleural effusion tumor cells (PTCs) to increase sensitivity of pleural effusion evaluation in malignant pleural mesothelioma (MPM) as compared to standard cytological analysis by the pathologist
- Secondary Outcome Measures
Name Time Method - To investigate the presence of circulating tumor cells (CTCs) in MPM patients and its correlation with the presence of PTCs<br /><br>- To indisputably confirm that PTCs in patients with MPM indeed represent MPM cells<br /><br>- To investigate the presence of tumor-derived circulating endothelial cells in MPM patients<br /><br>- To develop a flow cytometric method for the enumeration of PTCs in MPM patients<br /><br>- To investigate whether the number of PTCs, CTCs, CECs or immune cells is a prognostic marker for overall survival in MPM patients <br /><br>- To explore the occurrence of immune suppressive cells (e.g. regulatory T-cells and MDSC) and associated cytokines in the peripheral blood of MPM patients and their correlation with the occurrence of CTC